Type something and hit enter


 [KPJ HEALTHCARE BHD,改善其表现及业务策略以确保长期增长及盈利]


马来西亚业务继续保持领先,收入达7.973亿令吉,比去年同期的7.504亿令吉增长6%。本季度的收入较高,主要原因是患者发病次数和住院病人的复杂病例增加,尤其是对于KPJ Rawang,128张病床与2017年同一季度床位数相比增加了45%。其他医院录得双位数增长的住院人数包括KPJ Tawakkal,KPJ Klang,KPJ Pasir Gudang和KPJ Bandar Maharani,这也转化为本季度收入大幅增加。扣除税前及税前利润已增至6,390万令吉,较二零一七年同季的5,630万令吉增加13%,主要由于期内收入增加及联营公司业绩占比提高所致。


据报告,马来西亚分部资产总额为40亿120万令吉,较二零一七年三月三十一日的34亿6630万令吉增加15%。增加主要由于即将开业的医院,厂房及设备增加 - 正在建设中的BDC专科医院,KPJ Bandar Datn Onn和Miri专科医院。除物业,厂房及设备增加外,部分增幅亦由出售附属公司Lablink(M)私人有限公司给KL Kappa Sdn Bhd所收取的现金所致,导致柔佛医药保健现金及银行结余增加。

截至二零一八年三月三十一日止第一季,柔佛医药保健的现金流状况良好,经营现金流强劲。柔佛医药保健从投资活动中产生正现金流入,主要是由于在本季度结束时卖掉子公司Lablab(M)Sdn Bhd的盈利。收到的这笔款项有利于对KPJ Bandar Dato'Onn,KPJ BDC和KPJ Miri等新医院的建造,预计将在今年年底和明年完成。融资活动产生的现金流量有所改善,主要是由于本季度发行面值1亿令吉的伊斯兰中期票据(“IMTN”)。通过此次发行,截至2018年3月31日发行的IMTN总面值达10亿令吉。综上所述,净现金和现金等价物比上年同期增加了100%以上。


觉得不错就SHARE 出去吧。

James Ng

The Group’s revenue for the current quarter ended 31 March 2018 was RM822.9 million, an increase of 6% as compared to RM779.2 million in the corresponding quarter of the preceding year. The profit before zakat and tax for the 3 months ended 31 March 2018 was recorded at RM60.9 million, increased by 5% from RM57.8 million in 2017.

The Malaysia segment continues to excel, reported a revenue of RM797.3 million, an increase of 6% from RM750.4 million in the corresponding quarter of the preceding year. The revenue for the current quarter was higher mainly contributed by the increase in number of patient episodes and complex cases per inpatient particularly for KPJ Rawang with 128 beds increased by 45% as compared to number of beds in the same quarter in 2017. Other hospitals that recorded a double-digit growth in number of inpatients includes KPJ Tawakkal, KPJ Klang, KPJ Pasir Gudang and KPJ Bandar Maharani, that also translated to significant increment in revenue for this quarter. Profit before zakat and tax has increased to RM63.9 million during this quarter, an increase of 13% from RM56.3 million in the same quarter in 2017, mainly contributed by the increase in revenue and higher share of results of associates during the period.

The Group’s total assets as at 31 March 2018 was RM4,494.9 million, an increase of 12% as compared to RM3,998.6 million as at 31 March 2017.

Total assets from Malaysia segment was reported at RM4,001.2 million, an increase of 15% in comparison to RM3,466.3 million as at 31 March 2017. The increment was mainly attributable to the increase in property, plant and equipment for the soon-to-be opened hospitals such as BDC Specialist Hospital, KPJ Bandar Dato Onn and Miri Specialist Hospital which are currently under construction. Apart from the increase in property, plant and equipment, the increment was also contributed by the cash received arising from the partial disposal of a subsidiary, Lablink (M) Sdn Bhd to KL Kappa Sdn Bhd which lead to the increase of the Group's cash and bank balances.

For the first quarter ended 31 March 2018, the Group’s cash flows position is healthy with strong operating cash flow. The Group generated positive cash inflows from investing activities, mainly contributed by the purchase consideration received from partial disposal of interest in subsidiary, Lablink (M) Sdn Bhd towards the end of the current quarter. The proceed received was off-setted against the development of new hospitals, including KPJ Bandar Dato’ Onn, KPJ BDC and KPJ Miri, which are expected to be completed towards end of this year and next year. Cash flows from financing activities has improved mainly due to issuance of Islamic Medium Term Notes (“IMTN”) for a nominal value of RM100 million during this quarter. With this issuance, total nominal value of IMTN issued as at 31 March 2018 is amounted to RM1 billion. With all the above, net cash and cash equivalent has increased by more than 100% as compared to the same period of the preceding year.

For the financial year ending 31 December 2018, the Group will continue to improve its performance and enhancing its business strategies to ensure long-term growth and profitability. The number of outpatient and inpatient continues to grow within 3.6% to 5.3%, and hence this support the Group growth strategies that were already in place. The Group recognizes that rising in cost will continue to be the challenges in 2018, hence in ensuring consistent improvement of EBITDA and PBZT margin, the Group will focus on discipline cost management through innovation approaches in operational excellence from financial and other related aspects. As for other segments, the Group will continue to remain focused and putting in robust strategy in delivering an improved results.

If you think this post is beneficial, please share it.

James Ng

Back to Top